Becatecarin

Generic Name
Becatecarin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C33H34Cl2N4O7
CAS Number
119673-08-4
Unique Ingredient Identifier
A60X6MBU6G
Background

Becatecarin is a derivative of rebeccamycin.

Indication

Investigated for use/treatment in cancer/tumors (unspecified), liver cancer, gastric cancer, and leukemia (unspecified).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-02-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
42
Registration Number
NCT00005817
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer

First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
72
Registration Number
NCT00005997
Locations
🇺🇸

Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

🇺🇸

Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
Drug: becatecarin
First Posted Date
2003-01-27
Last Posted Date
2010-06-10
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
42
Registration Number
NCT00006017
Locations
🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy